SCHEMBL27020249

SCHEMBL27020249

CN1CCN(c2ccc(Nc3ncc(CN)cn3)cc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 2/20 0.61
ALK Q9UM73 2/20 0.55
EGFR P00533 2/20 0.53
CDK4 P11802 4/20 0.53
CCND3 P30281 4/20 0.53
CCND1 P24385 3/20 0.53
CCND2 P30279 3/20 0.53
LCK P06239 2/20 0.53
MAPK14 Q16539 2/20 0.53
ADRA2A P08913 1/20 0.52
ADRA2C P18825 1/20 0.52
STAT6 P42226 2/20 0.52
INSR P06213 1/20 0.51
MAP4K1 Q92918 1/20 0.51
CCNA2 P20248 2/20 0.50
CDK2 P24941 2/20 0.50
CCNK O75909 1/20 0.50
CDK9 P50750 1/20 0.50
CDK6 Q00534 1/20 0.50
AURKA O14965 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2951233 0.85 ALK (0.62) FLT3ALKEGFRCDK4CCND3
SCHEMBL30463630 0.82 ALK (0.65) FLT3ALKEGFRCCND3LCK
SCHEMBL2961783 0.82 EGFR (0.60) ALKEGFRCDK4CCND3CCND1
SCHEMBL4078840 0.80 EGFR (0.60) FLT3ALKEGFRCDK4LCK
SCHEMBL24458165 0.79 JAK2 (0.57) FLT3ALKEGFRCDK4CCND3
SCHEMBL4492001 0.79 SYK (0.62) ALKCDK4CCND3CCND1LCK
SCHEMBL28228697 0.77 LCK (0.60) ALKEGFRCDK4CCND3CCND1
SCHEMBL12064950 0.77 CDK4 (0.62) FLT3ALKEGFRCDK4CCND3
SCHEMBL30620425 0.76 CDK4 (0.67) FLT3ALKEGFRCDK4CCND3
SCHEMBL270386 0.76 CDK4 (0.67) FLT3ALKEGFRCDK4CCND3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018153-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF 2692372 ONTARIO, INC. (CA) 2024-01-18 US disclosed
US-20240018153-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF 2692372 ONTARIO, INC. (CA) 2024-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018153-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF ABCG2, ABCB1, ARSA FLT3 242/4885ALK 289/4885EGFR 2252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.